In a regulatory filing to stock exchanges today, Mankind Pharma Ltd, the fourth-largest pharmaceutical company in India by market share, said that its board has approved raising up to Rs 5,000 crore through non-convertible debentures in 3-4 distinct series with maturities of upto 48 months.

The company will raise up to Rs 5,000 crore through non-convertible debentures (NCDs) maturing in up to 48 months, according to a regulatory filing.

Mankind Pharma Ltd.’s board approved issuing Non-Convertible Debentures and Commercial Papers to raise up to ₹10,000 Crore, according to an exchange filing on Monday, September 30.

Mankind Pharma Limited announced today its plans to raise up to ₹100,000 crore through the issuance of non-convertible debentures (NCDs) and commercial papers (CPs). The decision was finalised at a Fund Raising Committee meeting held today.

Mankind Pharma will issue non-convertible debentures (NCDs) and commercial papers (CP) worth ₹5,000 crore. These funds will support acquisitions and long-term growth. NCDs will be in various series, secured by company assets,

The company, however, did not disclose how it aims to utilise the raised capital. In July this year, Mankind had announced the acquisition of Bharat Serums and Vaccines from Advent International for around Rs 13,

Mankind Pharma plans to raise up to Rs 10,000 crore through non-convertible debentures and commercial papers. The company will utilize the funds for growth and expansion.

Mankind Pharma plans to raise up to Rs 10,000 crore through non-convertible debentures and commercial papers. The board approved raising Rs 5,000 crore each via non-convertible debentures and commercial papers.

Mankind Pharma has been in focus since the company announced the acquisition of Bharat Serums and Vaccines from Advent International for an enterprise value of ₹13,630 crore.